Nicola Hewson

Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.

Antonio Piga, Renzo Galanello, Maria Domenica Cappellini et al. · PubMed · 2006 · 269 citations · Full text

Medicine, Hematology, Pharmacology +17

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study

Matthew J. Ellis, Antonio Llombart‐Cussac, David Feltl et al. · Journal of Clinical Oncology · 2015 · 239 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.

Renzo Galanello, Antonio Piga, Yves Bertrand et al. · PubMed · 2006 · 139 citations

Medicine, Hematology, Pharmacology +17

Abstract S6-04: Fulvestrant 500 mg versus anastrozole as first-line treatment for advanced breast cancer: Overall survival from the Phase II ‘FIRST’ study

J.F.R. Robertson, Antonio Llombart‐Cussac, David Feltl et al. · Cancer Research · 2015 · 18 citations

Medicine, Oncology, Pharmacology +15

The contribution of transfusion to HCV infection in England

Kate Soldan, Mary Ramsay, Andrew Robinson et al. · Epidemiology and Infection · 2002 · 15 citations · Full text

Medicine, Infectious Diseases, Microbiology +14